#USA #Class Action #San Francisco #Hagens Berman #Aardvark Therapeutics

Aardvark Therapeutics Securities Fraud Class Action

In a recent development that has sent shockwaves through the investment community, Aardvark Therapeutics, a clinical-stage biopharmaceutical company, is facing a securities class action lawsuit. The suit has been initiated by the esteemed law firm Hagens Berman Sobol Shapiro LLP, known for its robust advocacy on behalf of shareholders.

Key Background
Aardvark Therapeutics (NASDAQ: AARD) made headlines after its initial public offering (IPO) on February 13, 2025, aiming to revolutionize treatments for conditions related to bitter taste receptors. The stakes of this lawsuit are significant, as it targets investors who purchased Aardvark’s common stock during the IPO period and up until May 14, 2026.

The lawsuit alleges that the company, which focuses on developing therapies like ARD-101 for conditions such as Prader-Willi Syndrome (PWS), made misleading statements about the safety and efficacy of its products. It specifically accuses Aardvark of failing to disclose critical data that could impact investment decisions.

Details of the Allegations
According to the lawsuit, Aardvark Therapeutics was accused of the following key oversights:

• - Misrepresentation of Product Safety: The clinical data indicating that ARD-101 was less safe than what Aardvark had led investors to believe was allegedly omitted from public disclosures.
• - Serious Safety Concerns: There were claims of reversible cardiac observations noted during clinical trials, particularly at elevated dosages, which were not properly communicated to shareholders.
• - Inflated Clinical Promise: The lawsuit contends that the expectations surrounding Aardvark’s clinical trials—as evidenced by the Phase 3 HERO trial—were significantly overstated, causing a disconnect between the company’s public relations and the reality of their product development.

The Fallout
The situation escalated on February 27, 2026, when Aardvark announced a voluntary pause on its Phase 3 HERO trial due to safety concerns. This revelation led to a dramatic drop in the company’s stock price, falling over 56%. Following this, further bad news emerged on May 14, 2026, when the FDA placed a full clinical hold on all studies associated with ARD-101, resulting in a subsequent 32.1% drop in stock value.

Looking Forward
Hagens Berman's Reed Kathrein, who is spearheading the investigation, has expressed strong concerns regarding how Aardvark allegedly managed the disclosure of its clinical trials and their implications for investor sentiment. For investors who believe they may have been impacted by Aardvark’s actions, the deadline to file as a lead plaintiff under the class action suit is October 13, 2026.

What Investors Should Do
Aardvark investors who hold concerns regarding their investments are urged to reach out to Hagens Berman as soon as possible. The firm welcomes discussions regarding potential legal rights and options for recovery. Additionally, individuals with pertinent non-public information about Aardvark Therapeutics may consider reaching out to the firm or leverage the SEC’s whistleblower program, which offers rewards for information leading to successful enforcement actions.

As a globally recognized firm, Hagens Berman remains committed to holding corporations accountable for their actions and ensuring investors are informed about their rights and potential recourse.

For further inquiries, investors can call Hagens Berman at 844-916-0895 or visit their website for more information about the ongoing investigation.